Melodiol Global Health Limited (AU:ME1) has released an update.
Melodiol Global Health Limited reported a significant revenue increase of 91% for Q1 FY24, reaching $4.4 million, bolstered by strong performances from its subsidiaries Mernova Medicinal Inc. and Health House International. The company has also taken steps to reduce operating costs by 50% and remains focused on strategic growth and cost management. This follows a record annual revenue of $21.6 million in FY23, indicating a sustained trajectory of financial growth.
For further insights into AU:ME1 stock, check out TipRanks’ Stock Analysis page.
